celsci corporation nyse american cvm biotechnology company tests drugs treatment cancer autoimmune infectious diseases research development immunotherapy products celscis main product drug multikine immunotherapeutic agent designed fight cancer stimulating bodys immune system multikine currently phase iii clinical trials food drug administration fda multikine also referred leukocyte interleukin injection multikine phase ii testing patients head neck cancer early demonstrated tumorreducing january us cleared phase trial multikine designated orphan drug fda neoadjuvant therapy patients squamous cell carcinoma head total patients enrolled head neck cancer drug trial subsequently june company announced study missed primary celsci corporation founded germany maximilian de clara switzerland also president company resignation geert kersten de claras companys ceo since company went public year investment firm took company public later companys united states research development operations based baltimore maryland may us securities exchange commission issued cease desist order companys thenpresident maximilian de clara order stated august june de clara weeks late file forms documenting sales million celsci ceo geert kersten confirmed celsci paid analyst brokerage firm honolulu securities inc write research report companys stock though analyst claimed paid affect conclusion celscis stock celsci bought technology enabled regulation immune system responses licensing dutch company new york times reported celsci received unsolicited cash offer million unidentified person celsci arbitration suit filed october cro inventiv health breach contract arbitrator awarded celsci million damages cro failed enroll required number patients period years thus delaying clinical development multikine later fda lifted clinical hold imposed celsci august allowed company advance phase iii head neck cancer february celscis stock dropped trading halt issued news company released letter shareholders concerning phase iii june celsci announced study missed primary endpoint higher risk subgroup achieve improvement overall survival even though lower risk subgroup kersten declared company would apply fda approval drug despite studys missed endpoint following announcement celscis stock lost value one day trading halted least celsci also worked leaps ligand epitope antigen presentation system system therapeutic vaccines rheumatoid company also testing determine effective treatment aids washington post reported company conducting testing without backing fda couldnt agree study details said regulatory organization analysts quoted stating decision could cause company delays event redo research meet fda httpsenwikipediaorgwikicelscicorporation